Literature DB >> 18546627

Syngeneic mouse model of epithelial ovarian cancer: effects of nanoparticulate paclitaxel, Nanotax.

Katherine F Roby1, Fenghui Niu, Roger A Rajewski, Charles Decedue, Bala Subramaniam, Paul F Terranova.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18546627     DOI： 10.1007/978-0-387-68969-2_14

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  14 in total

1.  Nanoparticulate paclitaxel demonstrates antitumor activity in PC3 and Ace-1 aggressive prostate cancer cell lines.

Authors:  Sandra M Axiak-Bechtel; Senthil R Kumar; Kristin K Dank; Nicole A Clarkson; Kim A Selting; Jeffrey N Bryan; Thomas J Rosol; Jahna Espinosa; Charles J Decedue
Journal:  Invest New Drugs       Date:  2013-09-13       Impact factor: 3.850

2.  A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies.

Authors:  Stephen K Williamson; Gary A Johnson; Holly A Maulhardt; Kathleen M Moore; D S McMeekin; Thomas K Schulz; Gregory A Reed; Katherine F Roby; Christine B Mackay; Holly J Smith; Scott J Weir; Jo A Wick; Maurie Markman; Gere S diZerega; Michael J Baltezor; Jahna Espinosa; Charles J Decedue
Journal:  Cancer Chemother Pharmacol       Date:  2015-04-23       Impact factor: 3.333

3.  The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.

Authors:  Nicole E Campbell; James Greenaway; Jack Henkin; Roger A Moorehead; Jim Petrik
Journal:  Neoplasia       Date:  2010-03       Impact factor: 5.715

4.  Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors.

Authors:  Gaurav Bajaj; Mi Ran Kim; Sulma I Mohammed; Yoon Yeo
Journal:  J Control Release       Date:  2011-12-09       Impact factor: 9.776

5.  Influences of Gastrointestinal Microbiota Dysbiosis on Serum Proinflammatory Markers in Epithelial Ovarian Cancer Development and Progression.

Authors:  Diane E Mahoney; Prabhakar Chalise; Faith Rahman; Janet D Pierce
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

6.  Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac®) in a Rodent Model.

Authors:  James Verco; William Johnston; Michael Baltezor; Philip J Kuehl; Andrew Gigliotti; Steven A Belinsky; Anita Lopez; Ronald Wolff; Lauren Hylle; Gere diZerega
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2018-10-25       Impact factor: 2.849

7.  Development of a syngeneic mouse model of epithelial ovarian cancer.

Authors:  Bridget A Quinn; Fang Xiao; Laura Bickel; Lainie Martin; Xiang Hua; Andres Klein-Szanto; Denise C Connolly
Journal:  J Ovarian Res       Date:  2010-10-19       Impact factor: 4.234

8.  Phase I dose escalation safety study of nanoparticulate paclitaxel (CTI 52010) in normal dogs.

Authors:  Sandra M Axiak; Kim A Selting; Charles J Decedue; Carolyn J Henry; Deborah Tate; Jahna Howell; K James Bilof; Dae Y Kim
Journal:  Int J Nanomedicine       Date:  2011-10-11

9.  Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model.

Authors:  Andrew J Wilson; Whitney Barham; Jeanette Saskowski; Oleg Tikhomirov; Lianyi Chen; Hye-Jeong Lee; Fiona Yull; Dineo Khabele
Journal:  J Ovarian Res       Date:  2013-09-10       Impact factor: 4.234

10.  Low-dose glucocorticoids suppresses ovarian tumor growth and metastasis in an immunocompetent syngeneic mouse model.

Authors:  Kai-Ti Lin; Shu-Pin Sun; Jui-I Wu; Lu-Hai Wang
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.